Häupl T, Ringe J, Erggelet C, Kaps C, Burmester G-R, Sittinger M
Humboldt-Universität, Tucholskystr. 2, 10117 Berlin, Germany.
Z Rheumatol. 2003;62(Suppl 2):II46-9. doi: 10.1007/s00393-003-1214-3.
Current technologies of tissue engineering offer new strategies for the treatment of cartilage and bone defects. Beyond implantation of cell suspensions, second generation products of biomaterial enforced with in vitro preformed tissues are clinically applied. Ongoing research and development focus on differentiation factors and tissue protection. In search for sources of autologous cells which are easier to collect and which may serve for more complex tissues like osteochondral implants, mesenchymal stem cells are investigated. The design of in vitro experiments, which are required for these investigations, has produced tissue engineering technologies, which may serve for pathophysiology research in inflammatory joint diseases and for exploration of treatment strategies. These together with the advances in biological therapies of rheumatic diseases are the basis of new concepts, which promise application of tissue engineering also in inflammatory joint diseases.
当前的组织工程技术为软骨和骨缺损的治疗提供了新策略。除了植入细胞悬液外,结合体外预制组织的第二代生物材料产品已应用于临床。正在进行的研发工作聚焦于分化因子和组织保护。为了寻找更容易获取且可用于更复杂组织(如骨软骨植入物)的自体细胞来源,人们正在研究间充质干细胞。这些研究所需的体外实验设计产生了组织工程技术,可用于炎症性关节疾病的病理生理学研究以及治疗策略的探索。这些技术与风湿性疾病生物治疗的进展共同构成了新概念的基础,有望将组织工程应用于炎症性关节疾病。